Sonidegib
- Generic Name
- Sonidegib
- Brand Names
- Odomzo
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26F3N3O3
- CAS Number
- 956697-53-3
- Unique Ingredient Identifier
- 0RLU3VTK5M
- Background
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
- Indication
用于治疗那些在手术后或放射治疗后出现病情复发，或是不适合采用手术或放射治疗的局部晚期基底细胞癌（BCC）患者。BCC是常见皮肤癌，占所有非黑色素瘤病例的80%。
- Associated Conditions
- Refractory, locally advanced Basal cell carcinoma
- Associated Therapies
- -
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT02086552
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01757327
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath